All In Biotech

Drug Trial Radar · NCT04315324

Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

67

Planned (sponsor's estimate)

Start

Feb 8, 2021

Primary completion

Oct 28, 2025

Study completion Aug 1, 2028

Sponsor

Lead sponsor
SWOG Cancer Research NetworkResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Mar 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I/II trial studies the safety, side effects and best dose of OBI-3424 and how well it works in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Chemotherapy drugs, such as OBI-3424, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. OBI-3424 may reduce the amount of leukemia in the body.

Conditions

  • Recurrent T Acute Lymphoblastic Leukemia
  • Refractory T Acute Lymphoblastic Leukemia
  • Refractory T Lymphoblastic Lymphoma
  • T Lymphoblastic Lymphoma

Interventions

  • AKR1C3-activated Prodrug AST-3424Drug

    Given IV

  • Biopsy ProcedureProcedure

    Undergo biopsy

  • Biospecimen CollectionProcedure

    Undergo blood and CSF sample collection

  • Bone Marrow AspirationProcedure

    Undergo bone marrow aspirate

  • Computed TomographyProcedure

    Undergo CT scan

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD) (Phase I)Time frame: Up to 21 days
  2. Response rate (complete remission [CR] or CR with incomplete count recovery [CRi]) (Phase II)Time frame: Up to 5 years

Locations

163 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Kingman Regional Medical Center

    Kingman, Arizona

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • PCR Oncology

    Arroyo Grande, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Loma Linda University Medical Center

    Loma Linda, California

  • Children's Hospital of Orange County

    Orange, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Alfred I duPont Hospital for Children

    Wilmington, Delaware

  • Golisano Children's Hospital of Southwest Florida

    Fort Myers, Florida

  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital

    Hollywood, Florida

  • Johns Hopkins All Children's Hospital

    St. Petersburg, Florida

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia

  • Children's Healthcare of Atlanta - Arthur M Blank Hospital

    Atlanta, Georgia

  • Augusta University Medical Center

    Augusta, Georgia

  • Loyola Center for Health at Burr Ridge

    Burr Ridge, Illinois

  • Lurie Children's Hospital-Chicago

    Chicago, Illinois

  • Northwestern University

    Chicago, Illinois

  • University of Illinois

    Chicago, Illinois

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois

  • Loyola Medicine Homer Glen

    Homer Glen, Illinois

  • Northwestern Medicine Lake Forest Hospital

    Lake Forest, Illinois

  • Loyola University Medical Center

    Maywood, Illinois

  • Marjorie Weinberg Cancer Center at Loyola-Gottlieb

    Melrose Park, Illinois

  • UC Comprehensive Cancer Center at Silver Cross

    New Lenox, Illinois

  • University of Chicago Medicine-Orland Park

    Orland Park, Illinois

  • Southern Illinois University School of Medicine

    Springfield, Illinois

  • Mary Greeley Medical Center

    Ames, Iowa

  • McFarland Clinic - Ames

    Ames, Iowa

  • McFarland Clinic - Boone

    Boone, Iowa

  • McFarland Clinic - Trinity Cancer Center

    Fort Dodge, Iowa

  • McFarland Clinic - Jefferson

    Jefferson, Iowa

  • McFarland Clinic - Marshalltown

    Marshalltown, Iowa

  • Norton Children's Hospital

    Louisville, Kentucky

  • LSU Health Baton Rouge-North Clinic

    Baton Rouge, Louisiana

  • Our Lady of the Lake Physician Group

    Baton Rouge, Louisiana

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland

  • Bronson Battle Creek

    Battle Creek, Michigan

  • Wayne State University/Karmanos Cancer Institute

    Detroit, Michigan

  • Weisberg Cancer Treatment Center

    Farmington Hills, Michigan

Showing 40 of 163 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.